Drug Profile
Research programme: antibody therapeutics - Innovative Targeting Solutions/Merck
Alternative Names: HuTARG™ antibodies - Innovative Targeting Solutions/MerckLatest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Innovative Targeting Solutions; Merck & Co
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Unspecified in Canada
- 28 Jul 2020 No recent reports of development identified for research development in Unspecified in USA
- 21 Oct 2019 Innovative Targeting Solutions has patent protection for HuTARG platform in Europe